Fil LTD Uni Qure N.V. Transaction History

Fil LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$35.35 - $50.67 $2,050 - $2,938	-58 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$40.01 - $73.97 $2,440 - $4,512	-61 Reduced 51.26%	58 $3,000
Q4 2019 Feb 07, 2020	BUY	$37.13 - $74.62 $4,418 - $8,879	119 New	119 $9,000
Q3 2019 Nov 13, 2019	SELL	$39.36 - $76.8 $11.7 Million - $22.7 Million	-296,169 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$52.76 - $82.19 $6.5 Million - $10.1 Million	-123,223 Reduced 29.38%	296,169 $23.1 Million
Q1 2019 May 13, 2019	BUY	$27.39 - $68.41 $2.17 Million - $5.42 Million	79,209 Added 23.28%	419,392 $25 Million
Q4 2018 Feb 13, 2019	SELL	$22.8 - $33.93 $11.2 Million - $16.7 Million	-491,829 Reduced 59.11%	340,183 $9.8 Million
Q3 2018 Nov 09, 2018	SELL	$29.75 - $43.08 $2.17 Million - $3.15 Million	-73,011 Reduced 8.07%	832,012 $30.3 Million
Q2 2018 Aug 10, 2018	BUY	$21.96 - $39.94 $19.9 Million - $36.1 Million	905,023 New	905,023 $34.2 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

Stay updated on Fil LTD with notifications on news.